Terns Pharmaceuticals Inc (TERN)

Jan 8, 2025, 4:05 PM EST - 9 days ago

Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 4:05 PM EST - 15 days ago

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Dec 4, 2024, 1:18 PM EST - 6 weeks ago

Terns's stock soars as analysts cheer leukemia data — and predict more gains

Dec 3, 2024, 8:01 AM EST - 6 weeks ago

Terns Pharma broadens beyond obesity drugs with upbeat data in leukemia trial

Nov 19, 2024, 7:52 AM EST - 2 months ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

AMRN SLN

Nov 18, 2024, 4:05 PM EST - 2 months ago

Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors

Nov 15, 2024, 11:19 AM EST - 2 months ago

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

AMGN LLY NVO VKTX

Sep 25, 2024, 10:30 AM EDT - 4 months ago

Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst

Sep 13, 2024, 1:30 PM EDT - 4 months ago

Undercovered Stock Picks From September 6-12: Lithium, Uranium, Gold, & Plastic

ATLX BRZE DOCN EGO PL SLVM SMR

Sep 12, 2024, 7:00 PM EDT - 4 months ago

Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 10, 2024, 10:50 PM EDT - 4 months ago

Terns Announces Pricing of Upsized $150.15 Million Public Offering

Sep 10, 2024, 10:25 AM EDT - 4 months ago

Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive

Sep 9, 2024, 4:01 PM EDT - 4 months ago

Terns Announces Proposed Public Offering

Sep 9, 2024, 9:58 AM EDT - 4 months ago

Terns Pharmaceuticals Stock Is Soaring on Good Data for Weight-Loss Pill

Sep 9, 2024, 9:12 AM EDT - 4 months ago

Top 2 Health Care Stocks That May Collapse This Quarter

IMVT

Sep 9, 2024, 7:48 AM EDT - 4 months ago

Terns Pharmaceuticals' stock soars 30% after biotech posts positive results in trial of weight-loss drug in pill form

Sep 9, 2024, 7:34 AM EDT - 4 months ago

Terns Pharmaceuticals' oral obesity drug cuts weight by 4.9% in early study

Sep 9, 2024, 7:05 AM EDT - 4 months ago

Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

Jul 29, 2024, 4:05 PM EDT - 6 months ago

Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition

Jun 21, 2024, 6:30 PM EDT - 7 months ago

Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA's 84th Annual Scientific Sessions and Upcoming Conference Participation

Jun 3, 2024, 4:10 PM EDT - 8 months ago

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

May 30, 2024, 8:05 AM EDT - 8 months ago

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 17, 2024, 4:05 PM EDT - 8 months ago

Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day

May 15, 2024, 12:33 PM EDT - 8 months ago

Mizuho still recommends Terns Pharma as a cheap entry to the weight-loss-drug craze

May 13, 2024, 8:05 AM EDT - 8 months ago

Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates

May 8, 2024, 4:05 PM EDT - 9 months ago

Terns Pharmaceuticals Announces Leadership Changes

May 7, 2024, 4:05 PM EDT - 9 months ago

Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024

Apr 29, 2024, 4:05 PM EDT - 9 months ago

Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation

Apr 10, 2024, 4:05 PM EDT - 10 months ago

Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer

Mar 28, 2024, 3:02 PM EDT - 10 months ago

This small-cap stock is expected to take off — if its weight-loss pill trial succeeds

Mar 14, 2024, 4:05 PM EDT - 11 months ago

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

Mar 11, 2024, 4:05 PM EDT - 11 months ago

Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia

Feb 27, 2024, 4:05 PM EST - 11 months ago

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

Feb 7, 2024, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)

Feb 7, 2024, 8:05 AM EST - 1 year ago

Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer

Jan 17, 2024, 3:40 PM EST - 1 year ago

The weight loss drug market may soon get more crowded – here are the companies trying to enter the booming space

VKTX GPCR

Jan 4, 2024, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 29, 2023, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit

Nov 27, 2023, 4:05 PM EST - 1 year ago

Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer

Nov 14, 2023, 8:05 AM EST - 1 year ago

Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates

Nov 13, 2023, 8:05 AM EST - 1 year ago

Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023

Nov 9, 2023, 8:05 AM EST - 1 year ago

Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences

Oct 19, 2023, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals to Participate in Upcoming Investor Conferences

Oct 16, 2023, 8:05 AM EDT - 1 year ago

Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia

Oct 9, 2023, 9:19 AM EDT - 1 year ago

Terns Pharmaceuticals: Business Model Does Not Impress

Aug 8, 2023, 4:15 PM EDT - 1 year ago

Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates

Aug 3, 2023, 5:05 PM EDT - 1 year ago

Terns Pharmaceuticals Announces Leadership Transition

Jul 20, 2023, 1:11 PM EDT - 1 year ago

Terns Pharmaceuticals: Facing Impressive Competition, But Not Completely Out Of Its Depth

Jul 18, 2023, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss TERN-701 and Advances in the Treatment Landscape for Chronic Myeloid Leukemia

Jun 26, 2023, 4:05 PM EDT - 1 year ago

Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADA's 83rd Annual Scientific Session and Upcoming Events